On 16th January 2026, healthcare professionals from across the UK came together in Manchester for a dedicated, multidisciplinary education event focused on improving care for patients with Broncho-Pulmonary Carcinoids (BPCs).
The full-day programme was designed to ensure clinicians across all specialities and care settings are equipped with the most up-to-date knowledge on the diagnosis, treatment and long-term management of this (not so) rare and complex disease. Sessions covered the entire patient pathway, from early diagnosis to advanced disease management and survivorship.
A particular highlight of the day was the invaluable contribution of patient representatives from our community. We were delighted to welcome three active members (pictured): Melanie Lucas (Atypical lung carcinoid), Kate Quirk (Typical carcinoid) and Lisa Webb (Atypical lung carcinoid). They shared powerful personal insights into their diagnostic journeys, including experiences of misdiagnosis and the challenges of accessing appropriate specialist expertise for lifelong care. Their voices played a crucial role in grounding clinical discussions in real-world patient experience.
Alongside key clinical updates, the event shone a spotlight on unmet patient needs and helped shape a roadmap for future improvements in care at a national level.
Attendees also benefited from valuable networking opportunities and collaborative discussions aimed at strengthening multidisciplinary working and driving progress across the UK.
Educational sessions explored optimal surveillance strategies for patients with BPCs, survivorship programmes for those living with neuroendocrine cancer following surgery, and best practice in the management of metastatic broncho-pulmonary carcinoids.
This included discussions on systemic therapies and Peptide Receptor Radionuclide Therapy (PRRT).
Professor Was Mansoor (pictured left), one of the UK’s leading specialists in lung neuroendocrine tumours, commented:
“The Christie Manchester now sees a high throughput of broncho-pulmonary patients (also known as Lung NETs), and it is important to establish a clearly defined patient pathway to ensure consistent, high-quality care for this group. This event reinforced the importance of education, collaboration and patient involvement in improving outcomes for those affected. We hope now for significant advancement in shaping ongoing national efforts to optimise care for the future.”
Professor Matt Evison (pictured far right) Clinical Director for Lung Cancer & Thoracic Surgery at Manchester University NHS Foundation Trust said:
“…A key message from the day was that we can, and we must do more to standardise care and improve outcomes for patient diagnosed with bronchopulmonary carcinoids (BPCs). There was a very strong call to arms to develop a national optimal pathway for BPCs and standardised diagnostic work up through collaboration across expert neuroendocrine and thoracic diagnostic & oncology organisations. A number of actions will be taken forward from the meeting.”
